Brendan O'Malley

Brendan O'Malley

Auto-generated profile, based on publicly available information

Brendan O'Malley

Unilever Research and Development, Sharnbrook, Bedford MK44 1LQ, United Kingdom

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2006 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RNRebecca Notman
Rebecca Notman
MNMassimo Noro
Massimo Noro
BOBrendan O'Malley
Brendan O'Malley
JAJamshed Anwar
Jamshed Anwar

26 October 2002 in Molecular Simulation
Verified
Journal Article
Closed access
GOGeorge Opletal
George Opletal
TPTim Petersen
Tim Petersen
BOBrendan O'Malley
Brendan O'Malley
ISIan Snook
Ian Snook
DMDougal G. McCulloch
Dougal G. McCulloch
IYIrene Yarovsky
Irene Yarovsky
An improved method for the modelling of carbon structures based on a hybrid reverse Monte Carlo (HRMC) method is presented. This algorithm incorporates an accurate environment dependent interaction potential (EDIP) in conjunction with the commonly used constraints derived from experimental data. In this work, we compare this new method with other modelling results for a small system of 2.9 g/cc amorphous carbon. We find that the new approach greatly improves the structural description, alleviating the common problem in standard reverse Monte Carlo method (RMC) of generating structures with a high proportion of unphysical small rings. The advantage of our method is that larger systems can now be modelled, allowing the incorporation of mesoscopic scale features.

17 November 2009 in Circulation
Verified
Journal Article
Closed access
PDF file
OFOscar H. Franco
Oscar H. Franco
JMJoseph M. Massaro
Joseph M. Massaro
JCJacky Civil
Jacky Civil
MCMark R. Cobain
Mark R. Cobain
BOBrendan O'MAlley
Brendan O'MAlley
RDRalph B. D'AGostino
Ralph B. D'AGostino
Background— We evaluated the progression of the metabolic syndrome (MetS) and its components, the trajectories followed by individuals entering MetS, and the manner in which different trajectories predict cardiovascular disease and mortality. Methods and Results— Using data from 3078 participants from the Framingham Offspring Study (a cohort study) who attended examinations 4 (1987), 5 (1991), and 6 (1995), we evaluated the progression of MetS and its components. MetS was defined according to the Adult Treatment Panel III criteria. Using logistic regression, we evaluated the predictive ability of the presence of each component of the MetS on the subsequent development of MetS. Additionally, we examined the probability of developing cardiovascular disease or mortality (until 2007) by having specific combinations of 3 that diagnose MetS. The prevalence of MetS almost doubled in 10 years of follow-up. Hyperglycemia and central obesity experienced the highest increase. High blood pressure was most frequently present when a diagnosis of MetS occurred (77.3%), and the presence of central obesity conferred the highest risk of developing MetS (odds ratio, 4.75; 95% confidence interval, 3.78 to 5.98). Participants who entered the MetS having a combination of central obesity, high blood pressure, and hyperglycemia had a 2.36-fold (hazard ratio, 2.36; 95% confidence interval, 1.54 to 3.61) increase of incident cardiovascular events and a 3-fold (hazard ratio, 3.09, 95% confidence interval, 1.93 to 4.94) increased risk of mortality. Conclusions— Particular trajectories and combinations of factors on entering the MetS confer higher risks of incident cardiovascular disease and mortality in the general population and among those with MetS. Intense efforts are required to identify populations with these particular combinations and to provide them with adequate treatment at early stages of disease.

1 May 2008 in Computer Physics Communications
Verified
Journal Article
Closed access
GOG. Opletal
G. Opletal
TPT.C. Petersen
T.C. Petersen
BOB. O'Malley
B. O'Malley
ISI.K. Snook
I.K. Snook
DMD.G. McCulloch
D.G. McCulloch
IYI. Yarovsky
I. Yarovsky

21 August 2008 in Bulletin of Mathematical Biology
Verified
Journal Article
Open access
PDF file
JWJ. A. D. Wattis
J. A. D. Wattis
BOB. O’malley
B. O’malley
HBH. Blackburn
H. Blackburn
LPL. Pickersgill
L. Pickersgill
JPJ. Panovska
J. Panovska
KJK. G. Jackson
K. G. Jackson
Individuals with elevated levels of plasma low density lipoprotein (LDL) cholesterol (LDL-C) are considered to be at risk of developing coronary heart disease. LDL particles are removed from the blood by a process known as receptor-mediated endocytosis, which occurs mainly in the liver. A series of classical experiments delineated the major steps in the endocytotic process; apolipoprotein B-100 present on LDL particles binds to a specific receptor (LDL receptor, LDL-R) in specialized areas of the cell surface called clathrin-coated pits. The pit comprising the LDL–LDL-R complex is internalized forming a cytoplasmic endosome. Fusion of the endosome with a lysosome leads to degradation of the LDL into its constituent parts (that is, cholesterol, fatty acids, and amino acids), which are released for reuse by the cell, or are excreted. In this paper, we formulate a mathematical model of LDL endocytosis, consisting of a system of ordinary differential equations. We validate our model against existing in vitro experimental data, and we use it to explore differences in system behavior when a single bolus of extracellular LDL is supplied to cells, compared to when a continuous supply of LDL particles is available. Whereas the former situation is common to in vitro experimental systems, the latter better reflects the in vivo situation. We use asymptotic analysis and numerical simulations to study the longtime behavior of model solutions. The implications of model-derived insights for experimental design are discussed.

1 September 2005 in The Journal of Physical Chemistry B
Verified
Journal Article
Closed access
JPJ. Penfold
J. Penfold
ESE. Staples
E. Staples
SUS. Ugazio
S. Ugazio
ITI. Tucker
I. Tucker
LSL. Soubiran
L. Soubiran
HBH. Buron
H. Buron